Financial Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) and Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Alnylam Pharmaceuticals and Apellis Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1	5	18	0	2.71
Apellis Pharmaceuticals	0	7	11	2	2.75

Alnylam Pharmaceuticals presently has a consensus price target of $298.09, suggesting a potential upside of 21.72%. Apellis Pharmaceuticals has a consensus price target of $49.94, suggesting a potential upside of 62.32%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Institutional & Insider Ownership

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alnylam Pharmaceuticals and Apellis Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.83 billion	17.28	-$440.24 million	($2.62)	-93.47
Apellis Pharmaceuticals	$396.59 million	9.65	-$528.63 million	($2.03)	-15.16

Alnylam Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Alnylam Pharmaceuticals and Apellis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-15.86%	N/A	-8.38%
Apellis Pharmaceuticals	-34.97%	-103.11%	-28.96%

Summary

Apellis Pharmaceuticals beats Alnylam Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.